Microdosing Tirzepatide Chart: Dosing Schedule and What the Evidence Shows

A microdosing tirzepatide chart maps out weekly doses that sit below 2.5 mg — the lowest of the six FDA-approved amounts. Unlike the approved titration schedule, none of those lower steps has been tested in a large clinical trial. Below you will find a week-by-week low-dose schedule, the approved dosing chart beside it for comparison, and a straight account of what the evidence does and does not support.

Microdosing tirzepatide chart: the low-dose introduction schedule

Below is a four-week low-dose introduction schedule of the kind used when a clinician wants a patient to begin well under the approved starting dose. Every value in it sits beneath 2.5 mg, the lowest FDA-approved tirzepatide dose, which means none of these steps has been evaluated in a randomized controlled trial. It is shown here for reference — not as a schedule to follow independently.

Note what this schedule does not tell you: whether to continue past week four, at what rate, or toward what endpoint. Those decisions depend on how an individual responds, and they are the reason low-dose approaches require clinical supervision rather than a printable chart. A clinician may hold a patient at a step, move back down, extend the interval, or stop entirely.

For scale: the lowest FDA-approved tirzepatide dose is 2.5 mg once weekly — twenty times the first step above — and the lowest dose evaluated as a maintenance dose in the pivotal weight-management trial was 5 mg.

What a microdosing tirzepatide chart actually represents

Microdosing describes taking a weekly dose below the approved 2.5 mg minimum — 1 mg or 1.5 mg, for instance. A second version keeps a standard dose but stretches the interval between injections, or skips weeks. Neither appears in the approved labeling.

The practice spread during the 2025 GLP-1 shortages, when compounded preparations made non-standard amounts widely available and supply pressure encouraged stretching what patients had. Interest continued afterward, driven mostly by two hopes: fewer gastrointestinal side effects, and lower monthly cost.

Both hopes are reasonable. Neither has been confirmed by the kind of research that established what tirzepatide does at approved doses.

What the research shows about low-dose tirzepatide

Tirzepatide's effect on body weight is dose-dependent. In SURMOUNT-1, the pivotal 72-week weight-management trial, mean body-weight reduction rose with each studied dose. The lowest dose that was evaluated as a maintenance dose was 5 mg — twice the starting dose, and several times any typical microdose.

That absence is the central point. The claim that a sub-2.5 mg dose delivers meaningful metabolic benefit is not disproven — it is untested. Reports supporting it are largely anecdotal: clinician observation, patient self-report, and social media. Some physicians working in obesity medicine do use lower-than-label dosing in specific situations and report reasonable outcomes, but they generally describe this as individualizing care while the evidence catches up, not as an established protocol.

Risks a microdosing tirzepatide chart does not show

• The boxed warning applies. Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodents, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Dose does not change that.
• Serious adverse events remain possible — pancreatitis, gallbladder disease, kidney injury from dehydration, and hypersensitivity reactions have all been reported with GLP-1 therapy.
• Long-term effects are unknown. Sustained low-dose use over years has not been studied. Neither has the metabolic effect of indefinite sub-therapeutic exposure.
• Stopping brings regain. A 2025 systematic review and meta-analysis in Lancet eClinicalMedicine, pooling 18 randomized controlled trials and 3,771 adults, found average weight regain of 5.63 kg after GLP-1 receptor agonist discontinuation.
• Compounded preparations are not FDA-approved. They are prepared by a licensed pharmacy to fill an individual prescription and are not reviewed by the FDA for safety, effectiveness, or quality before marketing.

When a clinician uses a lower tirzepatide dose

Individualized dosing is ordinary medical practice, and it is not the same thing as microdosing. A clinician may hold a patient at a dose that is working, slow a titration that is producing intolerable nausea, extend an interval, or stop treatment altogether. What distinguishes that from following an internet chart is that it is a documented decision, made for one identified patient, by someone who can see their history and monitor the result.

Microdosing tirzepatide chart: frequently asked questions

Sources

• FDA-approved prescribing information for tirzepatide (Zepbound and Mounjaro).
• SURMOUNT-1: tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
• Weight regain after discontinuation of GLP-1 receptor agonists: systematic review and meta-analysis of 18 randomized controlled trials. Lancet eClinicalMedicine, 2025.